Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma - 11/08/23
Highlights |
• | Postoperative adjuvant therapy was significantly related to two-year RFS. |
• | TACE, T + A, and the combination of these two approaches were comparable in reducing HCC early recurrence without severe complications. |
Abstract |
Background |
The effects of postoperative adjuvant therapy for high-risk recurrent hepatocellular carcinoma (HCC) in immunotherapy are still under investigation. This study evaluated the preventive effects and safety of postoperative adjuvant therapy, including atezolizumab, and bevacizumab, against the early recurrence of HCC with high-risk factors.
Methods |
The complete data of HCC patients who underwent radical hepatectomy with or without postoperative adjuvant therapy after two-year follow-up were analyzed retrospectively. The patients were divided into high-risk or low-risk groups based on HCC pathological characteristics. High-risk recurrence patients were divided into postoperative adjuvant treatment and control groups. Due to the difference in approaches in postoperative adjuvant therapies, they were divided into transarterial chemoembolization (TACE), atezolizumab, and bevacizumab (T + A), and combination (TACE+T + A) groups. The two-year recurrence-free survival rate (RFS), overall survival rate (OS), and associated factors were analyzed.
Results |
The RFS in the high-risk group was significantly lower than that in the low-risk group (P = 0.0029), and the two-year RFS in the postoperative adjuvant treatment group was significantly higher than that in the control group (P = 0.040). No severe complications were observed in those who received atezolizumab and bevacizumab or other therapy.
Conclusion |
Postoperative adjuvant therapy was related to two-year RFS. TACE, T + A, and the combination of these two approaches were comparable in reducing the early recurrence of HCC without severe complications.
Le texte complet de cet article est disponible en PDF.Keywords : Postoperative adjuvant therapy, Immune checkpoint inhibitors, Hepatocellular carcinoma recurrence, Atezolizumab, Bevacizumab, Radical resection
Abbreviations : HCC, ICIs, TACE, RFS, OS, HBV, MVI, CTCAE5.0, CT, MRI, AFP, TKIs, CI, PSM, AST, BCLC, ALT, ALB, TBil, PT, FDA
Plan
Vol 47 - N° 7
Article 102165- août 2023 Retour au numéro
Article précédent
- Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study
- Wenwu Wan, Hao Zhang, Tao Ji, Li Zhang, KaiGuo Luo, Ding Xiong
- Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients
- Luciana Carneiro Pena, Cláudia Alves Couto, Bernardo Henrique Mendes Correa, Luisa Fabiana Queiroz Ferrua, Guilherme Grossi Lopes Cançado, Luciana Costa Faria, Eliane Viana Mancuzo, Teresa Cristina Abreu Ferrari
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?